Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.

BACKGROUND: Our recently reported finding of rapid bi-exponential elimination of free prostate-specific antigen (PSA) after radical retropubic prostatectomy in patients with moderately elevated PSA levels, which contrasted a very slow, linear elimination of PSA complexed to alpha-1-antichymotrypsin...

Full description

Bibliographic Details
Main Authors:	Björk, T, Schalken, J, Wittjes, W, Ljungberg, B, Lilja, H
Format:	Journal article
Language:	English
Published:	2001

Similar Items

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
by: Olsson, A, et al.
Published: (2005)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
by: Becker, C, et al.
Published: (2001)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
by: Lilja, H
Published: (2001)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
by: Törnblom, M, et al.
Published: (2001)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
by: Sävblom, C, et al.
Published: (2005)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
by: Steuber, T, et al.
Published: (2005)

Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor.
by: Malm, J, et al.
Published: (2000)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
by: Ylikoski, A, et al.
Published: (2001)

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
by: Janssen, S, et al.
Published: (2006)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
by: Olsson, A, et al.
Published: (2004)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Uji diagnostik prostate spesific antigen (PSA) pada keganasan prostat
by: , DAHESIHDEWI, Andaru, et al.
Published: (2002)

Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
by: Denmeade, SR, et al.
Published: (2001)

Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
by: Kurek, R, et al.
Published: (2003)

PSA is dead, long live PSA.
by: Vickers, A, et al.
Published: (2012)

Erratum: Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level (British Journal of Urology International 87 (638-642))
by: Törnblom, M, et al.
Published: (2001)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
by: Roddam, A, et al.
Published: (2005)

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

Standardization of two immunoassays for human glandular kallikrein 2.
by: Haese, A, et al.
Published: (2003)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
by: Becker, C, et al.
Published: (2000)

GnRH analogue use in postmenopausal hyperandrogenism: long-term remission.
by: Gueorguiev, M, et al.
Published: (2012)

GnRH analogue use in postmenopausal hyperandrogenism: long-term remission
by: Gueorguiev, M, et al.
Published: (2011)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
by: Janssen, S, et al.
Published: (2004)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer.
by: Lilja, H
Published: (2008)

Expression of GnRH Receptor Type-II Correlates with Proliferation Activity in Endometriosis
by: Zucha, Muhammad A., et al.
Published: (2022)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
by: Haese, A, et al.
Published: (2000)

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.
by: Nurmikko, P, et al.
Published: (2000)